Evercyte showing EV cell factory capabilities at IGLD Symposium Frankfurt

Innovative biotech manufacturer Evercyte GmbH will present its latest advances in EV production ‘cell factories;’ to a joint symposium of the German Society for Extracellular Vesicles (GSEV) and German Stem Cell Network (GSCN) later this month.

The groups are meeting as part of the overall scientific symposium organised by the Interdisciplinary Group for Laboratory and Flow Cytometry (IGLD) in Frankfurt am Main, Germany.

EV cell factories

Evercyte will be an exhibitor at the event from Booth 6 at the Kap Europe Messe Frankfurt conference venue, showing its wide range of EV-related services and capabilities. These include ‘cell factories’ for standardized production of a range of extracellular vesicles (EVs) and mesenchymal stromal cells (MSCs).

Recent additions to the EV cell factories range include MSCs derived from adipose tissue (ASC/TERT300), bone marrow (BM-MSC/TERT292), placental amnion (P-MSC/TERT308), placenta (CP-MSC/TERT308), dental pulp (DPSC/TERT334) and Wharton’s jelly (WJ-MSC/TERT273).

These EV cell lines have been established under xeno-free conditions, with full documentation of any manipulation step. This means they can seamlessly be transferred to a GMP facility for generation of a master cell bank to be used for production of clinical grade EVs.

Service offers

Evercyte’s displays will also highlight services that include lab-scale production of EVs from customer-derived cells, enrichment and characterization of EVs, testing biological activity of EVs for anti-fibrotic, anti-inflammatory, neo-angiogenic activity, wound-healing and other activities.

The Evercyte presence at the event will be led by its co-founder and CSO/COO Dr. Regina Grillari and Head of Science and Business Communications Dr. Giulia Corso.

Dr. Grillari commented: “The main focus of our discussions with our GSEV expert peers at IGLD Frankfurt will be to showcase the regenerative properties of our human mesenchymal stromal cells-derived EVs and the importance of our EV-based research in regenerative and transplant medicine, anti-tumor therapy and immunotherapy.”

For more information please contact Dr. Giulia Corso at giulia.corso(at)evercyte.com

About Evercyte

Evercyte is the leading provider of immortalized human primary-like cells (‘telomerized cells’) as well as novel cell lines for production of extracellular vesicles and is the partner of choice for innovative cell-based assays in the field of pharma, biotech, or cosmetic industries.

The core technology used for the establishment of these highly relevant human cell lines relies on the reactivation of the human telomerase enzyme. Besides customer-tailored cell line development as a one-stop shop, Evercyte is steadily expanding its catalogue of readily available cell lines for the production of extracellular vesicles from mesenchymal stromal cells using different tissues including adipose tissue, bone marrow, placenta, amnion or dental pulp.

By providing native extracellular vesicles from mesenchymal stromal cells Evercyte will make a significant contribution to the development of new therapeutic approaches. Additionally, Evercyte will promote its platform technology for the generation of recombinant EVs e.g. tissue targeting and targeted drug delivery.

Founded in 2011, the Vienna-based company successfully pioneered the development of tools and know-how necessary for the establishment of standardized high-throughput in vitro bioassays as well as relevant cell models and cell factories.

Learn more at: http://www.evercyte.com.

About IGLD Symposium 2023

Germany’s Interdisciplinary Group for Laboratory and Flow Cytometry was founded in 1995 with the aim of combining clinical practice, laboratory analysis and science. The IGLD almost immediately established its annual conference that focuses on combining theory with applied practice, clinical diagnostics and therapy.

Since the mid-1990s, the conference has developed into a translational symposium, at which specialists from various disciplines, including laboratory medicine, transfusion medicine, hematology, and oncology and basic researchers come together to exchange information on new developments in routine and related research areas. This includes an array of specialist societies that use the event for their own annual meetings.

The 2023 IGLD Symposium is a two-day event opening March 23 at the Messe Kap Europa in Frankfurt am Main and will involve groups including the German Society for Extracellular Vesicles (GSEV) that provides a forum for researchers specializing in extracellular vesicle studies to share their knowledge, along with others such as the German Stem Cell Network (GSCN) for basic and applied research, the German Society for Immunogenetics (DGI) the DVTA umbrella organization for medical technicians, and the INSTAND society for promoting quality assurance in medical laboratories.

The event is organised by IGLD in cooperation with the section of the German Society for Transfusion medicine and Immunohematology (DGTI) with further information at: https://www.igld.de/


Click on Evercyte EV cell factories for further information.
Click on Evercyte extracellular vesicle services  for further information.
Click on IGLD Symposium 2023 to see conference program.

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)lisavienna.at.